News stories about Veeva Systems (NYSE:VEEV) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Veeva Systems earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the technology company an impact score of 45.5903209928064 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Quorum Review IRB Launches Live IRB Interface for Veeva Vault eT – KAIT Jonesboro, AR – Region 8 News, weather, sports (kait8.com)
- What Does Veeva Systems Inc’s (NYSE:VEEV) Share Price Indicate? (finance.yahoo.com)
- Do Investors Feel Confident About Stock’s Future Direction? – Veeva Systems Inc. (NYSE:VEEV) (nasdaqjournal.com)
- Remarkable Stock of Recent Trading — Veeva Systems Inc. (VEEV) (stockmarketstop.com)
- Clinical Data Management Leaders Reveal Underlying Challenges Impacting Trial Timelines (finance.yahoo.com)
Shares of Veeva Systems traded down $0.72, hitting $82.84, during trading hours on Friday, MarketBeat reports. The company’s stock had a trading volume of 1,712,110 shares, compared to its average volume of 1,140,441. Veeva Systems has a 1-year low of $52.17 and a 1-year high of $85.00. The firm has a market capitalization of $12.12 billion, a P/E ratio of 90.04, a PEG ratio of 4.68 and a beta of 1.42.
Several brokerages have issued reports on VEEV. Deutsche Bank upped their price target on shares of Veeva Systems from $55.00 to $70.00 and gave the company a “hold” rating in a report on Friday, May 25th. Canaccord Genuity upped their price target on shares of Veeva Systems from $70.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. Zacks Investment Research downgraded shares of Veeva Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 1st. Stifel Nicolaus upped their price objective on shares of Veeva Systems from $67.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, February 28th. Finally, Morgan Stanley upped their price objective on shares of Veeva Systems from $72.00 to $76.00 and gave the company an “overweight” rating in a research note on Thursday, March 1st. Five investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Veeva Systems presently has a consensus rating of “Buy” and a consensus target price of $76.82.
In other news, CFO Timothy S. Cabral sold 50,000 shares of the firm’s stock in a transaction dated Wednesday, June 6th. The shares were sold at an average price of $81.75, for a total value of $4,087,500.00. Following the transaction, the chief financial officer now directly owns 30,000 shares in the company, valued at approximately $2,452,500. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Jonathan Faddis sold 612 shares of the firm’s stock in a transaction dated Monday, June 4th. The stock was sold at an average price of $79.50, for a total transaction of $48,654.00. Following the completion of the transaction, the senior vice president now owns 2,823 shares in the company, valued at $224,428.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 101,808 shares of company stock valued at $8,173,949. Company insiders own 15.97% of the company’s stock.
About Veeva Systems
Veeva Systems Inc provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, and internationally. The company offers Veeva Commercial Cloud, a suite of multichannel customer relationship management applications, which allow pharmaceutical and biotechnology companies to target and support sales and marketing to physicians, other healthcare professionals, and healthcare organizations through various touch points, including in-person, email, and online; and Veeva Vault, a cloud-based enterprise content management platform and suite of applications for managing commercial functions, including medical, sales, and marketing, as well as research and development functions, such as clinical, regulatory, and quality.
Receive News & Ratings for Veeva Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veeva Systems and related companies with MarketBeat.com's FREE daily email newsletter.